What else is in that vial? The fraud pattern with a court record.
The question
Harvard’s S. Bryn Austin, quoted in our research brief: “What else is in that vial?” Research-use-only (RUO) products carry no quality oversight. Dr. Froese reports seeing patient-supplied product lab reports at 60–70% purity — 30–40% unknown impurities.
The case on record
U.S. v. Matthew Kawa (Paradigm Peptides) — sentenced July 2026 to 70 months plus $5M forfeiture, roughly 54,000 customers. The operation used forged certificates of analysis, and its “testosterone-mimic” compounds contained actual steroids. It kept selling through FDA warning letters in 2020 and 2022. Full tracker: our sister site AllegedFraud covers the gray-market case file.
What the laboratories actually found
The 60–70% purity figure above is a clinician’s report of individual patient products. The peer-reviewed and platform-scale record is now considerably harder:
- Janvier, Vanhee et al., Talanta 2018 (PMID 30029448) — a Belgian public-health laboratory analyzed the ten falsified peptide drugs most frequently seized from illegal internet pharmacies (including ipamorelin, CJC-1295, sermorelin, GHRP-2, GHRP-6, epithalon, oxytocin and melanotan II — not BPC-157): purity of 5–75% for the cysteine-containing peptides; about 30% of samples with incorrect amino-acid sequences; two-thirds below 95% purity; inorganic arsenic up to ten times the ICH limit for injectable drugs; lead detected above the toxicity threshold in at least one sample.
- Finnrick Analytics (independent testing platform) — of more than 7,000 gray-market samples across compounds, roughly one in three fail basic expectations (CEO summary, February 26, 2026). For BPC-157 specifically (469 samples, 69 vendors), the failures are quantity — variance up to ±80% of label — and endotoxin in about 8% of samples; 68% of its vendors graded C or below.
- Mendias & Awan 2026 (preprint) — 6,441 consumer-market samples from 203 vendors: 41.6% to 71.1% failed basic quality standards, depending on the standard applied; 15% of endotoxin-tested samples had measurable endotoxin. (A preprint — labeled as such.)
- WIRED, September 15, 2026 — four injectables bought at a Brooklyn convenience store (labeled BPC-157, PT-141, retatrutide, NAD+) were sent to Finnrick: none contained a detectable match for its labeled ingredient.
- The NAD+ recall — GenoGenix’s injectable NAD+ was recalled in October 2025 at FDA’s most serious level (Class I) with endotoxin measured at 3,360 EU/mL; three patients were hospitalized with low blood pressure and uncontrollable shaking.
- Upstream, the ingredients themselves — FDA’s Import Alert 66-80 (GLP-1 active ingredients): of 48 ingredient sites FDA evaluated, 21% were noncompliant with manufacturing-quality requirements.
Documented harms
- FDA adverse-event hospitalizations are on record for gray-market peptide products (research brief, October 2026).
- Users of one gray-market brand reported prolonged fatigue, anxiety and anhedonia after BPC-157 (KFF, October 13, 2026).
- RAADFest, Las Vegas, July 2025: two women were intubated after booth injections — the product was never identified; Nevada regulators fined the parties a total of $35,000. The setting failure gets its own page: The Setting Is the Risk.
- CBP seized roughly 130,000 vials nationally between October 2025 and August 2026 — and stopped about 5,000 shipments of unapproved peptides from China at Cincinnati alone between December 2025 and March 2026 (CBP via news reporting).
The defense that exists
Real third-party testing (HPLC/mass spectrometry) and verifiable COAs — see Testing. Kim Constable (seller — labeled) teaches “How to Read a Peptide COA (Don’t Trust the Green Tick)” — good advice that applies to every seller’s paperwork, including hers.
Educational information only — not medical or legal advice. Status as of November 7, 2026. See Our Legal Mandate.